Company: ABBV
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001551152-25-000049
Chunk: 7

Company: AbbVie Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 2
Chunk 7
---
Vie’s worldwide net revenues: Three months endedSeptember 30,Percent changeNine months endedSeptember 30,Percent changeAt actual currency ratesAt constant currency ratesAt actual currency ratesAt constant currency rates(dollars in millions)2025202420252024ImmunologySkyriziUnited States$4,085 $2,778 47.0 %47.0 %$10,847 $6,774 60.1 %60.1 %International623 427 45.9 %40.2 %1,709 1,166 46.5 %46.1 %Total$4,708 $3,205 46.8 %46.0 %$12,556 $7,940 58.1 %58.0 %RinvoqUnited States$1,559 $1,170 33.3 %33.3 %$4,231 $2,912 45.3 %45.3 %International625 444 40.7 %36.5 %1,699 1,225 38.7 %38.7 %Total$2,184 $1,614 35.3 %34.1 %$5,930 $4,137 43.3 %43.3 %HumiraUnited States$619 $1,765 (65.0)%(65.0)%$2,165 $5,896 (63.3)%(63.3)%International374 462 (18.9)%(20.5)%1,129 1,415 (20.2)%(19.1)%Total$993 $2,227 (55.4)%(55.7)%$3,294 $7,311 (55.0)%(54.8)%NeuroscienceVraylarUnited States$931 $873 6.7 %6.7 %$2,592 $2,338 10.9 %10.9 %International3 2 31.5 %32.3 %7 5 38.0 %41.8 %Total$934 $875 6.7 %6.7 %$2,599